Home > Publications Database > Modifiable risk factors and symptom progression in dementia over up to 8 years-Results of the DelpHi-MV trial. > print

001     275938
005     20250126000532.0
024 7 _ |a 10.1002/dad2.70050
|2 doi
024 7 _ |a pmid:39811699
|2 pmid
024 7 _ |a pmc:PMC11730075
|2 pmc
024 7 _ |a altmetric:173120204
|2 altmetric
037 _ _ |a DZNE-2025-00160
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Blotenberg, Iris
|0 P:(DE-2719)9001870
|b 0
|e First author
|u dzne
245 _ _ |a Modifiable risk factors and symptom progression in dementia over up to 8 years-Results of the DelpHi-MV trial.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1737367013_5001
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This study investigated the association between modifiable factors and symptom progression in dementia over up to 8 years.Multilevel growth curve models assessed the role of modifiable risk factors (low education, hearing impairment and its treatment, depression, physical inactivity, diabetes and its treatment, smoking, hypertension and its treatment, obesity, alcohol consumption, social isolation, and visual impairment) on cognitive and functional trajectories in 353 people with dementia.Higher education was associated with higher initial cognitive status but faster decline. Antidiabetic medication was associated with slower cognitive decline, whereas depression and visual impairment were linked to low baseline functioning and faster cognitive decline.Several modifiable risk factors influenced symptom progression. Education initially had a protective effect, whereas depressive symptoms were linked to worse symptom progression. Treatment of comorbidities (diabetes, visual impairment) could have a positive impact on dementia symptoms. Modifiable risk factors are promising targets for tertiary prevention.Modifiable risk factors were associated with symptom progression in dementia over up to 8 years.More education was associated with higher initial cognitive status but faster decline.Depressive symptoms were linked to less favorable symptom progression.Treatment of comorbidities (diabetes, visual impairment) may positively impact the course of symptoms.Modifiable risk factors are promising targets for tertiary prevention.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer Disease
|2 Other
650 _ 7 |a activities of daily living
|2 Other
650 _ 7 |a anti‐diabetic medication
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a cognitive decline
|2 Other
650 _ 7 |a comorbidities
|2 Other
650 _ 7 |a depressive symptoms
|2 Other
650 _ 7 |a education
|2 Other
650 _ 7 |a functional decline
|2 Other
650 _ 7 |a lifestyle
|2 Other
650 _ 7 |a medication
|2 Other
650 _ 7 |a visual impairment
|2 Other
700 1 _ |a Wittström, Felix
|b 1
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 2
|u dzne
700 1 _ |a Platen, Moritz
|0 P:(DE-2719)9001238
|b 3
|u dzne
700 1 _ |a Wucherer, Diana
|0 P:(DE-2719)2810631
|b 4
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 5
|u dzne
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 6
|u dzne
700 1 _ |a Thyrian, Jochen René
|0 P:(DE-2719)2290613
|b 7
|e Last author
|u dzne
773 _ _ |a 10.1002/dad2.70050
|g Vol. 17, no. 1, p. e70050
|0 PERI:(DE-600)2832898-X
|n 1
|p e70050
|t Alzheimer's & dementia / Diagnosis, assessment & disease monitoring
|v 17
|y 2025
|x 2352-8729
856 4 _ |u https://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP2.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/275938/files/DZNE-2025-00160.pdf
856 4 _ |u https://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP2.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/275938/files/DZNE-2025-00160.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:275938
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001870
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810763
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001238
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810631
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2000040
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2290613
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZH DEMENT-DADM : 2022
|d 2024-12-31
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-31
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:09:24Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:09:24Z
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-31
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-08T17:09:24Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-31
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZH DEMENT-DADM : 2022
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-31
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 0
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 1
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 2
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1510100
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21